AliveCor has suffered another setback in its long-running patent case against Apple. Today, the US Court of Appeals for the Federal Circuit has upheld a decision that the medical device makerâs EKG patents are not actually patentable. As a result, the Apple Watch wonât face a second import ban from the International Trade Commission (ITC).
This back and forth between AliveCor and Apple began in 2021. AliveCor went to the ITC claiming Apple had infringed on its EKG patents. The ITC ruled in AliveCorâs favor, recommending an import ban that wouldâve prevented the sale of Apple Watches with the EKG feature in the US. However, it didnât immediately go into effect because the Patent Trial and Appeal Board also ruled that the three patents in question werenât valid. For the import ban to go forward, AliveCor wouldâve had to win its appeal of the PTAB decision â which it didnât.
âWe are deeply disappointed by the Courtâs decisions this morning and that the Court did not review the available secondary considerations, which the ITC found to be persuasive in their finding of validity,â says Sanjay Voleti, AliveCorâs chief business officer. âWe will continue to explore all available legal options, including potential appeals, to defend our position that our patents are valid and that Apple infringed our intellectual property rights.â
âWe thank the Federal Circuit for its careful consideration in this case. Appleâs teams have worked tirelessly over many years to develop industry-leading health, wellness and safety features that meaningfully impact usersâ lives, and we intend to stay on this path,â Apple spokesperson Fred Sainz tells The Verge.
AliveCor used the same legal strategy as Masimo, another medical device maker. However, Masimo was successful in its bid to get an ITC import ban against the Apple Watch. The main difference is Masimoâs patents were over the Apple Watchâs blood oxygen sensor, not its EKG tech. To get around the ITC import ban, Apple now disables the blood oxygen sensor in Apple Watches newly sold in the US.
Read the full article here